EUVIMEDEUVIMED entdecken
Crossref

Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry

Ewa Koscielniak iD, Beate Timmermann, Marc Münter, Jadwiga Weclawek-Tompol, Ruth Ladenstein iD, Felix Niggli iD, Gustaf Ljungman, Ines B Brecht iD, Bernd Blank, Erika Hallmen iD, Monika Scheer iD, Joerg Fuchs iD und 4 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.02673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Ewa Koscielniak und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Olgahospital, Stuttgart, Germany. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Rhabdomyosarcoma, Embryonal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To analyze and compare the indications, doses, and application methods of radiotherapy (RT) and their influence on prognosis of patients with localized rhabdomyosarcoma (RMS). METHODS One thousand four hundred seventy patients with localized RMS 21 years and younger entered on CWS-96, CWS-2002P, and SoTiSaR were eligible for the analysis. The median follow-up was 6.5 years (IQR, 3.3-9.5). RESULTS The 5-year event-free survival (EFS) and local control survival (LCS) for 910 (62%) irradiated versus nonirradiated patients were 71% versus 69% and 78% versus 73% ( P = .03), respectively. Ninety-five percent of patients in IRS I (90% embryonal RMS [eRMS]) were nonirradiated (EFS, 87%). Irradiated patients with IRS II had improved LCS (91% v 80%; P = .01) and EFS (not significant). In IRS III, EFS and LCS were significantly better for RT patients: 71% versus 56% ( P = 3.1e-06) and 76% versus 61% ( P = 4.1e-07). Patients with tumors in the head and neck region (orbita, parameningeal, and nonparameningeal) and in other sites had significantly better EFS and LCS and in parameningeal also overall survival (OS). The efficacy of low RT doses of 32 Gy (hyperfractionated, accelerated RT [HART]) and 36 and 41.4 Gy (conventional fractionated RT [CFRT]) in the favorable groups and higher doses of 44.8 Gy (HART) and 50.4 and 55.4 Gy (CFRT) in the unfavorable groups was comparable. Proton RT was used predominantly in head/neck—parameningeal (HN—PM) tumors, with similar EFS and LCS to photon RT. CONCLUSION RT can be omitted in patients with IRS I eRMS. RT improves LCS and EFS in IRS II and III. RT improves OS in patients with HN-PM, with proton RT comparable with photon RT. Doses of 32 Gy (HART) or 36 and 41.4 Gy (CFRT) had comparable efficacy in patients with favorable risk profiles and 44.8 Gy (HART) or 50.4 and 55.8 Gy (CFRT) in the unfavorable groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaRhabdomyosarcoma, EmbryonalHumansProtonsPrognosisProgression-Free SurvivalCombined Modality TherapyAntineoplastic Combined Chemotherapy Protocols

Substanzen

Protons

Autor:innen und Institutionen

  • Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Olgahospital, Stuttgart, Germany.
  • Medical Faculty, University of Tübingen, Tübingen, Germany.
  • West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany.
  • Hospital for Radiation Oncology, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany.
  • Department of Pediatric Hematology/Oncology and BMT, University of Wroclaw, Wroclaw, Poland.
  • Pediatric Oncology, St Anna Kinderspital, Vienna, Austria.

ORCID-Profile: Ewa Koscielniak, Ruth Ladenstein, Felix Niggli, Ines B Brecht, Erika Hallmen, Monika Scheer, Joerg Fuchs, Guido Seitz, Monika Sparber-Sauer, Thomas Klingebiel

Zitieren

APA

Koscielniak, E., Timmermann, B., Münter, M., Weclawek-Tompol, J., Ladenstein, R., Niggli, F., Ljungman, G., Brecht, I. B., Blank, B., Hallmen, E., Scheer, M., Fuchs, J., Seitz, G., Blattmann, C., Sparber-Sauer, M., & Klingebiel, T. (2023). Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02673

Vancouver

Koscielniak E, Timmermann B, Münter M, Weclawek-Tompol J, Ladenstein R, Niggli F, et al. Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02673

BibTeX
@article{Koscielniak2023,
  author = {Koscielniak, Ewa and Timmermann, Beate and Münter, Marc and Weclawek-Tompol, Jadwiga and Ladenstein, Ruth and Niggli, Felix and Ljungman, Gustaf and Brecht, Ines B and Blank, Bernd and Hallmen, Erika and Scheer, Monika and Fuchs, Joerg and Seitz, Guido and Blattmann, Claudia and Sparber-Sauer, Monika and Klingebiel, Thomas},
  title = {Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.02673}
}
Kostenlos starten →